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Ixmyelocel-T is a patient-specific, expanded, multicellu-
lar therapy evaluated in patients with lower extremity 
critical limb ischemia (CLI) with no options for revas-
cularization. This randomized, double-blind, placebo-
controlled, phase 2 trial (RESTORE-CLI) compared the 
efficacy and safety of intramuscular injections of ixmy-
elocel-T with placebo. Patients received one-time injec-
tions over 20 locations in a single leg and were followed 
for 12 months. Safety assessments included occurrence 
of adverse events. Efficacy assessments included time to 
first occurrence of treatment failure (TTF; major ampu-
tation of injected leg; all-cause mortality; doubling of 
total wound surface area from baseline; de novo gan-
grene) and amputation-free survival (AFS; major ampu-
tation of injected leg; all-cause mortality). A total of 77 
patients underwent bone marrow or sham aspiration; 72 
patients received ixmyelocel-T (48 patients) or placebo 
(24 patients). Adverse event rates were similar. Ixmyelo-
cel-T treatment led to a significantly prolonged TTF (P 
= 0.0032, logrank test). AFS had a clinically meaning-
ful 32% reduction in event rate that was not statistically 
significant (P = 0.3880, logrank test). Treatment effect in 
post hoc analyses of patients with baseline wounds was 
more pronounced (TTF: P < 0.0001, AFS: P = 0.0802, 
logrank test). Ixmyelocel-T treatment was well tolerated 
and may offer a potential new treatment option.
Received 8 November 2011; accepted 20 February 2012; advance online 
publication 27 March 2012. doi:10.1038/mt.2012.52
IntroductIon
Peripheral arterial disease (PAD) occurs in ~7% of people over 40 
and sharply increases with age to affect ~12–20% of Americans 
≥70 years of age.1–3 Critical limb ischemia (CLI) represents the 
most serious form of PAD and is characterized by ischemic rest 
pain with or without tissue loss (ulcers and/or gangrene).4 It is 
estimated 5–10% of PAD patients over 50 years of age will develop 
CLI within 5 years.4 CLI is associated with significant morbidity 
and mortality: up to 30% of patients will require an amputation 
within 1 year and another 25% will die of cardiovascular events.1,4 
The 10-year survival rate has been estimated to be as low as 10%.4
Treatment of CLI includes risk factor modification (quitting 
smoking and managing diet, exercise, diabetes, hyperlipidemia, 
hypertension, and use of antiplatelet medications), ischemic 
pain control, management of ischemic ulcers, and revasculariza-
tion either by open bypass surgery or endovascular approaches.4 
Although revascularization is a mainstay of treatment, it often is not 
feasible due to medical comorbidities or no anatomic options, and 
is associated with significant rates of complications.5–7 In addition, 
in CLI patients with tissue loss, survival and limb-related outcomes 
are poor as compared with CLI patients with rest pain only.8 Patients 
with severe ischemia who are unable to undergo revascularization 
or with a failed revascularization have limited options and amputa-
tion is often necessary.9 As it is estimated that there are 150,000–
300,000 new cases of CLI every year,4 there remains a significant 
need for less invasive therapeutic options in patients with CLI.
Several early clinical studies of bone marrow–derived mono-
nuclear cells have demonstrated promising safety and improved 
clinical outcomes.10,11 The goal for new therapies will be to increase 
perfusion enough to allow wound healing, resolution of rest pain, 
and limb salvage.8
Ixmyelocel-T is a patient-specific, expanded, multicellular 
therapy. In preclinical studies, it has been shown to have mul-
tifunctional properties including: tissue remodeling, immune 
modulation, and the promotion of angiogenesis. These pro-
cesses could potentially address the multiple underlying causes 
of severe, chronic ischemic cardiovascular diseases such as CLI. 
Ixmyelocel-T is produced from a small amount of a subject’s own 
bone marrow in an automated closed-culture system developed 
by the Sponsor. The process enhances bone marrow–derived 
mononuclear cells by expanding the mesenchymal stromal cells 
and alternately activated macrophages that have been reported to 
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augment the return of blood flow in animal models of ischemia 
(internal Sponsor documents). The ixmyelocel-T manufacturing 
process significantly expands cells that express the surface marker 
CD90 (mesenchymal cells), and also expands a CD14+ monocyte/
macrophage subset of CD45+ hematopoietic cells.
RESTORE-CLI was a phase 2, double-blind, placebo-controlled, 
randomized trial conducted with the objective of assessing both 
the safety and efficacy of ixmyelocel-T in patients with CLI and no 
options for revascularization. Results from an interim analysis have 
been previously reported;12 results from the completed trial are pre-
sented here.
results
A total of 86 patients at 18 active centers in the United States were 
randomly assigned to treatment groups between June 2007 and 
March 2010; patient follow-up was completed in March 2011. 
Figure 1 summarizes the flow of patients throughout the trial, 
including reasons for discontinuation. During the 30 days that 
were allowed between randomization and aspiration, nine patients 
withdrew from the study due to adverse events, lack of compli-
ance, or no longer meeting eligibility criteria. A total of 77 patients 
 proceeded with the study and underwent aspirations (or sham aspi-
rations for patients in the placebo group), and 72 patients received 
injections of either ixmyelocel-T or the placebo solution. Of these 
72 patients, 13 (18%) received injections in the thigh and calf and 
59 (82%) received injections in the thigh, calf, and foot (after a pro-
tocol amendment). All available data were included in the specified 
safety and efficacy summaries and analyses, regardless of whether 
the patient had completed the trial. Three of the six patients treated 
with ixmyelocel-T who did not complete the 12-month follow-up 
period had experienced one or more treatment failure events before 
they withdrew from the trial; the one control patient who did not 
complete the 12-month follow-up period did not experience a treat-
ment failure event before study withdrawal.
The characteristics of treated patients were similar between the 
two treatment groups at baseline (Table 1). In the ixmyelocel-T and 
Screened N = 113
Randomized to ixmyelocel-T
treatment N = 58
Aspirated N = 53
Aspirated (sham) N = 24
Treated N = 24
Treated N = 48
Not treated N = 0
Discontinued study N = 1
(other1)
Died N = 2
Completed N = 21
Completed N = 39
Died N = 3
Included in Safety Analyses
N = 53 (all patients aspirated)
Included in Safety Analyses
N = 24 (all patients aspirated)
Included in Efficacy Analyses
N = 48 (all patients injected)
Included in Efficacy Analyses
N = 24 (all patients injected)








Not aspirated N = 5 
(ineligible after enrollment,2 
lack of compliance,1 
adverse event,2)
Not aspirated N = 4 
(ineligible after enrollment,2 
adverse event,2)




























Figure 1 Patient recruitment and disposition throughout the trial. N, number of patients.
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control groups, 29 (60%) and 16 (67%) patients, respectively, had 
wounds present at baseline (P = 0.797). One ixmyelocel-T-treated 
patient (2%) had a glomerular filtration rate ≤30 ml/ min/1.73 m2, 
all others were >30 ml/min/1.73 m2.
safety
The occurrence of adverse events and serious adverse events was 
similar between the two treatment groups (Table 2). Almost all 
patients reported adverse events during the trial. The most com-
monly reported adverse events tended to be those characteristic 
of the disease process: pain in extremity, gangrene, cellulitis, and 
skin ulcer occurring in 17 (32%), 7 (13%), 5 (9%), and 6 (11%) 
ixmyelocel-T-treated patients and 4 (17%), 6 (25%), 6 (25%), and 
5 (21%) control patients, respectively.
Of the 77 patients who underwent aspiration (or sham aspira-
tion), two patients withdrew from the trial due to adverse events: 
one patient randomized to the ixmyelocel-T group withdrew due to 
a urinary tract infection, a serious adverse event, which hospitalized 
the patient and prevented him from receiving treatment injections 
within the product’s expiration window. The second patient, also 
in the ixmyelocel-T group, withdrew due to pain in the extremity 
on day 63. Neither event was felt by the investigator to be due to 
the aspiration procedure, the injection procedure, nor the (blinded) 
treatment.
There were four deaths (8%) in the ixmyelocel-T treatment 
group and two (8%) in the control group and none was considered 
related to treatment. In the ixmyelocel-T treatment group, three of 
the deaths occurred while patients were still participating in the trial 
(one patient died on day 148 from complications resulting from a 
hip fracture; one patient died on day 132 due to congestive cardiac 
failure and one patient died on day 333 due to renal impairment). 
The fourth ixmyelocel-T patient who died had completed the trial 
on day 361 but died from a glioblastoma on day 498. One of the 
patients who died in the control group died on day 37 of hypov-
olemic shock and the other control patient died on day 258 from 
a cardiac disorder. Each of the five patients who died while still 
ongoing in the trial contributed a death to the treatment failure end 
point and to the amputation-free survival (AFS) end point; the one 
patient who completed the study and then died did not contribute a 
death to either the treatment failure or the AFS end point.
As the study progressed, patients may have developed occlu-
sions in their previously placed stents, or the site principal inves-
tigator may have felt that the patient had developed an option to 
revascularize the extremity using endovascular techniques that 
were not possible at the time of initial evaluation. Three patients 
(two in the ixmyelocel-T group and one in the control group) at 
separate study sites had a stent placed in the injected leg during 
the trial. One ixmyelocel-T patient had a nonserious adverse event 
of “in-stent stenosis,” which resulted in a “stent placement of right 
common iliac artery” on day 63; this patient did not experience 
any treatment failure events. The second ixmyelocel-T patient 
had a serious adverse event of “bilateral lower extremity pain,” 
which resulted in “left iliac artery stent placement” on day 293; 
this patient experienced de novo gangrene, a treatment failure 
event, on day 318. The control patient had a nonserious adverse 
event of “right great toe amp site not healing,” which resulted in 
“angioplasty and stenting of new right superficial femoral artery 





(N = 24) P valuea
Gender, n (%) 0.303
 Male 34 (71) 14 (58)
 Female 14 (29) 10 (42)
Age, years [mean (SD)] 69.2 (13.2) 67.3 (11.6) 0.565
Race 0.749
 White 40 (83) 22 (92)
 Asian 1 (2) 0 (0)
 Hispanic or Latino 3 (6) 0 (0)
 Black or African American 4 (8) 2 (8)
 American Indian 0 (0) 0 (0)
Smoking status, n (%) 0.146
 Never smoked 8 (17) 4 (17)
 Current smoker 8 (17) 9 (38)
 Past smoker 32 (67) 11 (46)
BMI [mean (SD)] 26.9 (4.9) 28.3 (5.9) 0.276
Creatinine, µmol/l [mean (SD)] 1.2 (0.5) 1.1 (0.3) 0.394
Prior amputation below talus of 
injected leg, n (%)
8 (17) 2 (8) 0.479
Known diabetes, n (%) 21 (44) 15 (63) 0.211
Known on dialysis, n (%) 0 (0) 0 (0) —
Baseline wound(s), n (%) 29 (60) 16 (67) 0.797
GFR, n (%) 1.000
 ≤30 1 (2) 0 (0)
 >30 47 (98) 24 (100)
BMI, body mass index; GFR, glomerular filtration rate.
aP value from Fisher’s exact test for count data; from t-test for continuous data.





(N = 24) P valueb
Patients reporting AE, n (%) 47 (88.7) 23 (95.8) 0.424
Patients reporting AE that caused 
Discontinuation, n (%)
2 (3.8) 0 (0.0) 1.000
Patients reporting an SAE, n (%) 23 (43.4) 12 (50.0) 0.628
Patients who diedc, n (%) 4 (7.5) 2 (8.3) 1.000
Number of AEsd 281 141 —
Number of SAEsd 51 30 —
AEs occurring in ≥10% of patients
Pain in extremity 17 (32) 4 (17) 0.181
Gangrene 7 (13) 6 (25) 0.209
Cellulitis 5 (9) 6 (25) 0.087
Skin ulcer 6 (11) 5 (21) 0.303
Hypertension 6 (11) 2 (8) 1.000
Nausea 5 (9) 3 (13) 0.699
AE, adverse event; SAE, serious adverse event.
aControl patients had sham aspiration. bP value from Fisher’s exact test. cOne 
death occurred ~4.5 months after patient had completed trial. dAll events 
occurring on or after aspiration date are summarized, including those with 
missing date of onset.
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occlusion” on day 154; this patient experienced wound size dou-
bling, a treatment failure event, on day 91.
Serious adverse events occurred in 23 (43%) ixmyelocel-T-
treated patients and in 12 (50%) control patients. Only one seri-
ous adverse event was felt by the investigator to be possibly related 
to blinded treatment. One patient in the ixmyelocel-T treatment 
group developed wound sepsis on the first toe of the injected 
leg on day 34 that resulted in progressive amputations of the toe 
 culminating with a below-knee amputation on day 63.
There were five adverse event reports in the ixmyelocel-T treat-
ment group and one in the control group of injection site pain or 
pain in extremity/foot that the investigator felt was at least possibly 
related the blinded treatment. There was one additional report of 
a possibly related injection site reaction described as redness and 
a raised area at the injection sites, which started on day 3 in the 
control group. Other adverse events that were felt by the inves-
tigator to be at least possibly related to blinded treatment were a 
 burning sensation (occurring in one control patient beginning on 
day 0), cellulitis (one ixmyelocel-T-treated patient beginning on day 
14 and a separate occurrence on day 69), eczema on the injected 
leg  (ixmyelocel-T-treated patient beginning on day 1), and throm-
bophlebitis (ixmyelocel-T-treated patient beginning on day 86).
efficacy
Time to first occurrence of treatment failure (TTF) was signifi-
cantly longer for patients treated with ixmyelocel-T as compared 
with control patients (P = 0.0032, logrank test; Figure 2).The sur-
vival curves diverged early and the difference between groups was 
maintained throughout the 12-month follow-up period. The Cox 
proportional hazards (PH) analysis gave a treatment hazards ratio 
(HR) = 0.381, 95% confidence interval (CI) = (0.195, 0.744), con-
veying a significant reduction in the risk of treatment failure in 
the ixmyelocel-T treatment group of ~62% (P = 0.0047). Table 3 
details the contribution of individual events to the composite 
treatment failure end point and the total number of patients who 
experienced each end point. The percentage of patients experienc-
ing each of the individual events favored the ixmyelocel-T group 
with the largest differences between treatment groups seen for 
doubling of total wound surface area from baseline and de novo 
gangrene. A total of 19 (39.6%) ixmyelocel-T-treated patients and 
16 (66.7%) control patients experienced one or more of the treat-
ment failure events (P = 0.0451, Fisher’s exact test).
There was a trend for improved AFS in ixmyelocel-T-treated 
patients as compared with control patients, but the difference did 
not reach statistical significance (P = 0.3880, logrank test; Figure 3). 
The Cox PH analysis for AFS gave a treatment HR = 0.676, 95% 
CI = (0.276, 1.654). Of the 10 ixmyelocel-T-treated patients who 
experienced a major amputation of the injected leg, 7 (70%) had 
below-knee amputations and 3 (30%) had above-knee amputations. 
Three of the seven initial below-knee amputations were followed 
within 2 months by above-knee amputations. In the control group, 
six patients experienced a major amputation of the injected leg, four 
(67%) were below-knee, and 2 (33%) were above-knee. None of the 
initial below-knee amputations were followed by an above-knee 
amputation.
A post hoc analysis of TTF and AFS was performed on the 





























67% (16) 33% (8)
60% (29) NA
84.5 (17.0  NA)
(304.0  NA)40% (19)
Figure 2 time to first occurrence of treatment failure for all patients 
injected. Kaplan–Meier survival plot of time to treatment failure (major 
amputation of injected leg, all-cause mortality, doubling of total wound 
surface area from baseline, de novo gangrene) for all patients injected. 
Censored observations are indicated by “+” symbols. CL, confidence 





























33% (8) 67% (16)
75% (36) NA
NA (258.0  NA)
(NA    NA)25% (12)
Figure 3 Amputation-free survival for all patients injected. Kaplan–
Meier survival plot of amputation-free survival (major amputation of 
injected leg or all-cause mortality) for all patients injected. Censored 
observations are indicated by “+” symbols. CL, confidence limits; NA, 
not available.
table 3 contribution of treatment failure events to composite end 
point for all patients injected
event















Major amputation of the 
injected leg
6 10 (20.8) 4 6 (25.0)
All-cause mortality 2 3 (6.3) 1 2 (8.3)
Doubling in total wound 
surface area from baseline
5 7 (14.6) 7 7 (29.2)
De novo gangrene 6 7 (14.6) 4 5 (20.8)
Any end point 19 (39.6) 16 (66.7)
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population that will be studied in phase 3. Thirteen of the 29 
(44.8%) ixmyelocel-T-treated patients with wounds at baseline 
and 14 of the 16 (87.5%) control patients with wounds at baseline 
experienced a treatment failure event (P = 0.0098, Fisher’s exact 
test). In these patients with wounds at baseline, TTF was longer 
in the ixmyelocel-T group than the control group (P < 0.0001, 
logrank test; Figure 4). The Cox PH analysis gave an HR = 0.225, 
95% CI = (0.103, 0.490), indicating a risk reduction of treatment 
failure events of ~78% (P = 0.0002). For AFS, 6 of the 29 (20.7%) 
ixmyelocel-T-treated patients with baseline wounds and 7 of the 
16 (43.8%) control patients with baseline wounds experienced a 
major amputation of the injected leg or death (P = 0.1687, Fisher’s 
exact test). AFS was longer in the ixmyelocel-T-treated patients 
with baseline wounds than in control patients with wounds at 
baseline (P = 0.0802, logrank test; Figure 5). The HR = 0.391, 
95% CI = (0.131, 1.164) from the Cox PH analysis, indicating 
an approximate 61% reduction in risk for ixmyelocel-T-treated 
patients with baseline wounds (P = 0.0915).
dIscussIon
Patients afflicted with CLI have a poor quality of life and high 
rate of limb loss.1,4 To date, revascularization of the ischemic limb 
either by endovascular or open surgical approaches is the main-
stay of therapy.1,4 Yet revascularization is associated with a sig-
nificant incidence of failure and complications and is not a viable 
option in up to 50% of patients.13 In patients with no viable surgi-
cal options, avoiding an operative procedure such as an ampu-
tation is in the best interest of the patient. After undergoing a 
major amputation, these patients often suffer from surgical com-
plications either from the amputation procedure itself or from 
their postoperative clinical state.5,14 Less invasive medical thera-
pies efficacious in the treatment of CLI are, therefore, desirable. 
Treatment with ixmyelocel-T would require patients to undergo a 
small volume bone marrow aspiration under conscious sedation 
followed by intramuscular injections into the affected limb. Both 
of these procedures provide far fewer complications than those 
connected to an amputation or surgical revascularization. This 
trial provides encouraging evidence that treatment with ixmy-
elocel-T is safe and beneficial in treating lower extremity CLI in 
a “no-option” population. Because this was primarily a phase 2 
safety trial, the sample size was not chosen to try to demonstrate 
statistical differences between treatment groups. Despite a small 
number of patients treated, there was improved TTF and AFS 
in ixmyelocel-T-treated patients as compared with controls. In 
addition, the treatment effect for both TTF and AFS was even 
more pronounced in patients who entered the trial with baseline 
wounds. Treatment with ixmyelocel-T, a patient-specific, multi-
cellular therapy, was safe with a comparable percentage of patients 
reporting both adverse events and serious adverse events.
Unique features of ixmyelocel-T treatment result from the small 
volume (~50 ml) bone marrow aspiration and cell manufacturing 
processes which significantly expand key cell types. Clinical studies 
on therapeutic angiogenesis using bone marrow–derived progeni-
tor cells have commonly harvested 500 ml or more of bone mar-
row.10 The large volume of bone marrow harvest required by other 
stem cell therapy techniques is significantly more uncomfortable for 
the patients and may entail general anesthesia and/or postprocedure 
blood transfusion with increased potential for morbidity and mor-
tality.15 Ixmyelocel-T has the potential to overcome these limitations 
by significantly expanding the number of the cells critical to regen-
eration and repair through automated, closed ex vivo culture. This 
allows the bone marrow sample to be collected from a small volume 
aspiration (~50 ml) under local anesthesia or conscious sedation 
without general anesthesia in a procedure that lasts ~15 minutes. 
Ixmyelocel-T also contains large numbers of mesenchymal stromal 
cells and alternatively activated macrophages and potentially repre-
sents a more standardized, and possibly more potent, therapy than 
fresh bone marrow preparations.
Potential limitations include difficulties with an inadequate 
aspirate preventing processing into ixmyelocel-T. Two patients from 
the same site had an inadequate aspirate, meaning that there was 






















Control with baseline wound
Ixmyelocel-T with baseline wound
Control with baseline wound
Ixmyelocel-T with baseline wound
No. of Subjects Event Censored Median survival (95% CL)
16
29
88% (14) 13% (2)
55% (16) NA
28.0 (7.0  91.0)
(177.0    NA)45% (13)
Figure 4 time to first occurrence of treatment failure for all patients 
who had baseline wounds. Kaplan–Meier survival plot of time to treat-
ment failure (major amputation of injected leg, all-cause mortality, dou-
bling of total wound surface area from baseline, de novo gangrene) for post 
hoc analysis of patients who had baseline wounds. Censored observations 






















Control with baseline wound
Ixmyelocel-T with baseline wound
Control with baseline wound
Ixmyelocel-T with baseline wound
No. of Subjects Event Censored Median survival (95% CL)
16
29
44% (7) 56% (9)
79% (23) NA
NA (78.0   NA)
(NA    NA)21% (6)
Figure 5 Amputation-free survival for all patients who had baseline 
wounds. Kaplan–Meier survival plot of amputation-free survival (major 
amputation of injected leg or all-cause mortality) for post hoc analysis of 
patients who had baseline wounds. Censored observations are indicated 
by “+” symbols. CL, confidence limits; NA, not available.
Molecular Therapy  vol. 20 no. 6 june 2012 1285
© The American Society of Gene & Cell Therapy
Ixmyelocel-T to Treat CLI: RESTORE-CLI
A third sample, while being processed, had a breach in the closed 
system and was not suitable to be shipped back to the site. There was 
a fourth instance in which the product was initially thought to be 
nonsterile but this test result was discovered to be a false positive; the 
external contract laboratory performing the sterility testing deter-
mined that the “positive” test was a result of a sterility breach during 
their testing procedure. Although events like these can occur, they 
happen infrequently and can be overcome with additional process-
ing controls or aspiration technique training.
Limitations of this trial include the fact that it was not pow-
ered a priori for efficacy evaluations and the small number of 
patients. A second limitation centers on the collection of hemo-
dynamic data. Though ankle and toe pressures and indexes were 
collected at screening, follow-up measures of the same parameter 
were often unavailable or not done due to amputations or non-
compressible or nonpulsatile arteries. As a result, there were insuf-
ficient data to analyze ankle and toe pressures and indexes. In this 
CLI patient population, while it would have been optimal to have 
full data sets on hemodynamic parameters, these measurements 
are in fact substitutes for the hard end points of patient outcomes. 
Additionally, it is unclear by what mechanism(s) cellular therapy 
might have an effect.9–11 If it is through a nonarteriogenic pathway, 
then these hemodynamic indexes may not show improvement 
and yet the cellular therapy may mechanistically yield clinically 
meaningful and beneficial patient outcomes.
Every effort was made to maintain a double-blind nature for 
this trial with separate physicians or designees obtaining the aspi-
rations or sham aspirations, and administering treatment injec-
tions, using masked syringes. There was little difference between 
treatment groups in adverse event reports of injection site pain 
or reactions investigators felt were at least possibly related to 
ixmyelocel-T treatment that might unblind a patient or investiga-
tor to treatment assignment. However, it is unknown whether the 
occurrence of one of these adverse events might have led to suspi-
cions of treatment group assignment on a patient-by-patient basis. 
Despite these limitations, the results were statistically significant 
for TTF, a more objective end point than those used in other cell 
therapy studies.11,15,16
In conclusion, there were no major safety issues related to 
ixmyelocel-T treatment in patients with no-option CLI. Treatment 
with ixmyelocel-T improved TTF in treated patients as compared 
with controls. These results suggest that treatment with ixmy-
elocel-T has the potential to be a promising treatment option in 
patients with CLI who are unable to undergo revascularization. 
Based on these data, a larger phase 3 pivotal trial is warranted.
MAterIAls And Methods
Trial design. This randomized, double-blind, placebo-controlled, mul-
ticenter trial was conducted in accordance with Declaration of Helsinki 
principles and approved by the appropriate institutional review boards. All 
patients gave written informed consent. Patients included were those 18–90 
years old with a diagnosis of CLI, defined as persistent, recurring ischemic 
rest pain ≥2 weeks duration and/or ulceration or gangrene of the toe or 
foot, with toe systolic pressure ≤50 mm Hg (or absent palpable pedal pulse 
in patients with diabetes) or ankle systolic pressure ≤70 mm Hg. Other 
inclusion criteria included infrainguinal occlusive disease deemed by the 
site principal investigator not amenable to revascularization (confirmed by 
angiographic imaging results or by color flow duplex ultrasound obtained 
within the 6 months before randomization), controlled blood pressure 
with or without antihypertensive therapy, and adequate antiplatelet ther-
apy established before randomization. Statin therapy was required unless 
contraindicated. Major exclusion criteria were patients who had a previ-
ous amputation of the talus or above on the preidentified index (injected) 
leg; a known, failed ipsilateral revascularization procedure within 2 weeks 
before randomization; active infection or infection of the target extremity 
manifested by fever, purulence, and severe cellulitis; wet gangrenous tissue; 
poorly controlled diabetes (hemoglobin A1c >10%); aortoiliac disease with 
>50% stenosis; or a wound with exposed tendon or bone. To protect the 
blinding of the trial, the physician or appropriately trained designee who 
performed the bone marrow or sham aspirations was different from the 
physician or designee who later administered the treatment injections and 
who followed the patients thereafter.
Patients who satisfied selection criteria were randomized 2:1 to receive 
either ixmyelocel-T injections or placebo injections (electrolyte solution) 
in a preidentified index leg. Injections were administered one time, 
intramuscularly, over 20 locations in the lower thigh, calf, and foot. Patients 
were then followed for 12 months for safety and efficacy outcomes.
Patients randomized to receive injections of ixmyelocel-T had a small 
sample of bone marrow (~50 ml) obtained by a percutaneous aspiration 
from the posterior iliac crest. Patients in the control group underwent a 
sham aspiration whereby the aspiration needle was inserted through the 
skin but the periosteum of the iliac crest was not perforated.
Safety analyses were conducted on the Safety Population, defined as 
all patients who were randomized and underwent aspiration, regardless 
of whether or not they received their randomized treatment. The primary 
safety end point was adverse events; aspiration- and treatment-emergent 
adverse events are summarized. Efficacy analyses were conducted on the 
Efficacy Population, defined as all randomized patients who received 
treatment injections. The primary efficacy end point was TTF, with AFS 
as a secondary efficacy end point. TTF was defined as the earliest trial day 
on which any of the following treatment failure events occurred: major 
amputation of the injected leg, all-cause mortality (death), doubling of total 
wound surface area from baseline, and de novo gangrene. Major amputation 
was defined as an amputation at or above the talus on the injected leg. For 
wound size doubling, the patient must have come into the study with a 
wound (i.e., had a baseline wound) to be eligible to contribute to the event. 
AFS was defined as the number of days from injection to the first trial day 
on which a major amputation of the injected leg or death occurred.
Preparation of investigational product. The mononuclear cells from 
the bone marrow of patients in the ixmyelocel-T treatment group were 
cultured to expand the mesenchymal stromal cells (CD90) and alter-
nately activated macrophages (CD14+). The process retains cells of other 
hematopoietic cell lineages from the bone marrow. Ixmyelocel-T product 
specifications include the total number of viable cells and the proportion 
of CD90+ cells and CD45+ cells, which together define >98% of the nucle-
ated cells in the product. The ixmyelocel-T product was generated in an 
automated closed-culture system over 12 ± 1 days at manufacturing facil-
ity of Aastrom Biosciences in Ann Arbor, Michigan, and then transported 
to the clinical site under “cold temperature” storage conditions (between 
0 and 12 °C), which was maintained in a qualified shipping container. 
The ixmyelocel-T product is produced and administered as a “unit dose,” 
defined as the total number of cells produced from bone marrow–derived 
mononuclear cells via the Sponsor’s manufacturing process. The expansion 
potential of bone marrow–derived mononuclear cells varies modestly from 
patient to patient. Product lot release specifications required that the total 
number of viable cells in the product be in the range of 35–295 × 106 cells, 
and be primarily composed of two cell types: mesenchymal stromal cells 
(defined by the CD90+ cell surface marker) and hematopoietic stem, pro-
genitor, and mature cells (defined by the CD45+ hematopoietic cell surface 
marker). These two markers are mutually exclusive and define two distinct 
populations of cells. The overall cell viability was measured by membrane 
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integrity by dye exclusion and was 70% or greater. Some excipients, which 
were added as stabilizing agents, changed over the life of the study. The 
final volume of the investigational product delivered to the site was 10 ml. 
The composition of the electrolyte solution (placebo) was composed of the 
same excipients used in the formulation of the ixmyelocel-T product.
A health-care provider, trained in aseptic technique and unblinded 
to treatment, prepared 20 syringes from the patient-labeled bags (either 
ixmyelocel-T product or placebo) that were prepared at Aastrom’s 
manufacturing site. Each syringe contained ~0.5 ml of investigational 
product. The fluid in the syringes was obscured with frosted tape to ensure 
the physician or designee administering the injections would not notice 
a visual difference between syringes. Twenty injection sites in the index 
leg were mapped by marking four circumferential linear bands around 
the lower third of the thigh, the greatest diameter of the patient’s calf, 
and at one location proximal and one distal to the greatest calf diameter. 
Originally, five intramuscular injections of 0.5 ml were given along each 
band, at least 2.0 cm apart and 0.5 inches into the muscle, to include all 
major muscle groups. Subsequent to a protocol amendment, the number 
of circumferential bands was increased to five, to include injections 
between the interosseous muscles in the foot, and four injections were 
administered along each band. Patients were observed for injection-
related reactions for 2 hours postinjections (considered day 0) and were 
followed up with a phone call at day 3 and clinic visits on day 7 and at 
months 3, 6, 9, and 12 for safety and efficacy assessments.
Data safety monitoring board. An independent Data Safety Monitoring 
Board consisting of three physicians (an interventional cardiologist, a 
vascular surgeon, and a stem cell therapy physician) and one statistician 
reviewed deaths and all adverse events in an unblinded fashion on a quar-
terly basis.
Statistical analyses. Because this was primarily a phase 2 trial that assessed 
safety and efficacy, the sample size was not chosen to try to demonstrate 
statistical differences between treatment groups. A total of 86 patients were 
randomized. The randomization schedule was computer-generated and 
balanced to adjust the number of patients in each group at each center.
For a patient who did not experience an event, his/her last day of the 
trial was used to calculate the event-free interval. TTF and AFS were each 
assessed using Kaplan–Meier curves, with the P value from the logrank 
test also provided. In addition, Cox PH analyses were performed to obtain 
an estimate of the treatment effect. For each of the efficacy end points, 
the HR and its 95% CI from the Cox PH analysis are provided in order 
to describe the size of the treatment effect of ixmyelocel-T. SAS, version 
9.1.3, was used for all data summarization and analysis (SAS, Cary, NC).
There were two formal amendments to the original protocol. 
Important changes to the eligibility criteria were a modification to the 
upper age limit (i.e., increased from 82 years to 90 years) and patients 
with early-end-stage renal disease undergoing dialysis for <6 months 
were allowed. The randomization schema was updated from 1:1 to 2:1 
(ixmyelocel-T to placebo). Furthermore, as noted above, the injection 
pattern was modified from four circumferential bands of five injections 
in each band to five circumferential bands (including the foot) with four 
injections in each band.
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